Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
US-9827335-B2 · Nov 28, 2017 · US
Stabilized gold nanoparticle and contrast agent
US9549998B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9549998-B2 |
| Application number | US-66508608-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 27, 2008 |
| Priority date | Jun 28, 2007 |
| Publication date | Jan 24, 2017 |
| Grant date | Jan 24, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A kit for providing a contrast enhancer in a mammal for contrasting during imaging of the mammal comprises functionalized gold nanoparticles configured to be directed to one or more of a target organ, tissue and lesion of the mammal.
First claim
Opening claim text (preview).
What is claimed is: 1. A kit for providing a contrast enhancer in a mammal for contrasting during imaging of the mammal, the kit consisting of: gold nanoparticles functionalized with a biomolecule for engagement with a target portion of the mammal, wherein the gold nanoparticles are directly coated with bisphosphonate and gum arabic; and an aqueous solution of the gum arabic. 2. A kit as defined by claim 1 wherein the coated gold nanoparticles are functionalized with a bombesin molecule, and wherein the target portion of the mammal comprises a lesion. 3. A kit as defined by claim 1 wherein the coated gold nanoparticles are provided in a dosage sufficient to cause engagement between a target portion of the mammal in a ratio of at least 1 mg gold nanoparticles/gm of target portion of the mammal. 4. A kit as defined by claim 1 wherein the coated gold nanoparticles are configured to allow a period of at least about 24 hours after injection into the mammal before using an imaging apparatus to perform imaging on the mammal. 5. A kit as defined by claim 1 wherein the coated gold nanoparticles have a diameter of less than about 20 nm and the target portion of the mammal is the lungs. 6. A kit as defined by claim 1 wherein the coated gold nanoparticles have a diameter of greater than about 20 nm and the target portion of the mammal is one or more of the liver and the spleen. 7. A kit as defined by claim 1 wherein the coated gold nanoparticles are provided in a dosage of between about 2 and about 45 mg per kilogram body weight of the mammal. 8. A kit as defined by claim 1 wherein the coated gold nanoparticles are provided in a dosage of between about 1 and about 5 mg per kilogram body weight of the mammal. 9. A kit as defined by claim 1 wherein the target portion of the mammal comprises one or more of an organ, tissue or a lesion.
Assignees
Inventors
Classifications
Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title
- A61K49/0428Primary
Surface-modified nanoparticles, e.g. immuno-nanoparticles · CPC title
for non-human patients · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9549998B2 cover?
- A kit for providing a contrast enhancer in a mammal for contrasting during imaging of the mammal comprises functionalized gold nanoparticles configured to be directed to one or more of a target organ, tissue and lesion of the mammal.
- Who is the assignee on this patent?
- Kattumuri Vijaya, Katti Kattesh V, Boote Evan, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K49/0428. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).